Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11052
Title: | Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role? | Austin Authors: | Yip, G;Ekinci, Elif I ;Lee, S T;Jerums, George ;Grossmann, Mathis | Affiliation: | Department of Medicine, Austin Health, Heidelberg, Victoria, Australia | Issue Date: | 1-Apr-2010 | Publication information: | Internal Medicine Journal; 40(4): 300-3 | Abstract: | Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs. | Gov't Doc #: | 20529040 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/11052 | DOI: | 10.1111/j.1445-5994.2009.02143.x | Journal: | Internal Medicine Journal | URL: | https://pubmed.ncbi.nlm.nih.gov/20529040 | Type: | Journal Article | Subjects: | Adult Agranulocytosis.chemically induced.diagnosis.immunology Antibodies, Antineutrophil Cytoplasmic.biosynthesis.blood.physiology Carbimazole.adverse effects Female Humans |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.